Hepatitis D surgery

Jump to navigation Jump to search

Hepatitis Main Page

Hepatitis D

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Hepatitis D from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Hepatitis D surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis D surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis D surgery

CDC on Hepatitis D surgery

Hepatitis D surgery in the news

Blogs on Hepatitis D surgery

Directions to Hospitals Treating Hepatitis D

Risk calculators and risk factors for Hepatitis D surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2] Jolanta Marszalek, M.D. [3]

Overview

Treatment of hepatitis D does not involve surgery. Some procedures may be indicated for certain complications, such as ascites, in which peritoneal drainage may be performed. Liver transplantation may be indicated for: end-stage liver disease; liver failure secondary to HDV infection, for patients in which treatment with interferon is not indicated; and hepatocellular carcinoma.[1][2]

Surgery

The treatment of hepatitis D does not involve surgical procedures. However, some complications, such as ascites, may require interventional procedures such as peritoneal drainage.

Liver Transplantation

Liver transplant is indicated in patients with end-stage liver disease, or liver failure secondary to HDV infection, in whom treatment with interferon is not indicated.[1][2][3] These patients usually have a good outcome, with inhibition of HBV and HDV reinfection, when simultaneously treated with nucleoside and nucleotide analogues, and hepatitis B antibodies.[4] However, HDV remains latent and can be detected in the new liver for several months after the transplant. Therefore prevention of HBV reinfection should be maintained, in order to simultaneously avoid resurgence of HDV.[1]

After liver transplantation chances of reinfection of the the new liver, may be reduced with administration of HBsAg immunoglobulins. These reduce the levels of HBsAg in the patient to a point where HDV is eliminated, at the same time reducing HDV RNA levels. Long term administration of these immunoglobulins help to prevent re-infection of the graft.[5][3][6]

Liver transplantation has a good outcome, with more than 80% 5-year survival rate.[3]

References

  1. 1.0 1.1 1.2 Heidrich B, Manns MP, Wedemeyer H (2013). "Treatment options for hepatitis delta virus infection". Curr Infect Dis Rep. 15 (1): 31–8. doi:10.1007/s11908-012-0307-z. PMID 23242761.
  2. 2.0 2.1 Wedemeyer H, Manns MP (2010). "Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead". Nat Rev Gastroenterol Hepatol. 7 (1): 31–40. doi:10.1038/nrgastro.2009.205. PMID 20051970.
  3. 3.0 3.1 3.2 Hughes SA, Wedemeyer H, Harrison PM (2011). "Hepatitis delta virus". Lancet. 378 (9785): 73–85. doi:10.1016/S0140-6736(10)61931-9. PMID 21511329.
  4. Samuel D, Zignego AL, Reynes M, Feray C, Arulnaden JL, David MF; et al. (1995). "Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis". Hepatology. 21 (2): 333–9. PMID 7843702.
  5. Smedile A, Casey JL, Cote PJ, Durazzo M, Lavezzo B, Purcell RH; et al. (1998). "Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope". Hepatology. 27 (6): 1723–9. doi:10.1002/hep.510270636. PMID 9620349.
  6. Mederacke I, Filmann N, Yurdaydin C, Bremer B, Puls F, Zacher BJ; et al. (2012). "Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation". J Hepatol. 56 (1): 115–22. doi:10.1016/j.jhep.2011.06.016. PMID 21762665.

Template:WH Template:WS